Systematic review and meta-analysis of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry
The DESTINY-Breast04 trial has recently demonstrated survival benefits of trastuzumab-deruxtecan (T-DXd) in metastatic breast cancer patients with …
